This Could Be the Best GLP-1 Stock to Buy in 2025

The GLP-1 weight loss market is a massive one, with some analysts expecting it to be worth around $200 billion by 2031. Hype around weight loss drugs isn't new, but when people are losing more than 20% of their body weight, it creates considerable enthusiasm. And by sharing their results on social media, people are amping up that excitement to a whole new level.But to own a top drugmaker like Eli Lilly, which has an incredibly successful pair of GLP-1 drugs in Mounjaro and Zepbound, investors have to pay a significant premium -- 75 times its trailing earnings. That may be a bit steep given how competitive the GLP-1 market could become, as many healthcare companies are vying for a piece of that massive pie.If you're looking for a more reasonably priced investment, you may want to consider Amgen (NASDAQ: AMGN). Here's why I think it can be the best GLP-1 stock to buy this year.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool